Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

(4:35)

Novo Nordisk stock plunges on obesity shot trial results

(3:25)

Novo Nordisk - En Navidad también cuidamos nuestra salud - Cardiobascúlate

(1:21)

Novonordisk - El momento ha llegado... - Cardiobascúlate

(31)

Novonordisk - El momento ha llegado... - Cardiobascúlate

(1:14)

Novonordisk - En las etapas más importantes de tu vida - Cardiobascúlate

(28)

Novonordisk - En las etapas más importantes de tu vida - Cardiobascúlate

(1:14)

Join us for a career within Manufacturing

(1:42)

Join us for a career within Engineering

(1:59)

Meet Brittany, Engineering a Rewarding Career in Manufacturing

(1:25)

Meet Charlene, Leaders on the Line in U.S. Manufacturing

(1:12)

Meet Matt, Military Veteran Turned Logistics Leader

(1:24)

Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging

(4:8)

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

(4:1econd)

Novo Nordisk plunges after obesity drug trial disappoints | REUTERS

(1:31)

The spirit of our founders: The values and mindsets that created Novo Nordisk a century ago

(24:15)

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture

(4:47)

Novo Nordisk (Ozempic)

(3:45:26)

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company

(19:20)

How Novo Nordisk built an empire selling diabetes and weight-loss drugs

(2:16)

Novo Nordisk CEO Lars Jorgensen testifies before Senate on weight loss drugs pricing — 9/24/24

(2:15:10)

NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages

(4:29)

Novo Nordisk CEO defends high price off Ozempic and Wegovy

(5:)

Novo Nordisk CEO testifies before Senate on weight loss drug prices

(1:55)

Novo Nordisk shares sink on medicare price negotiation fears

(4:35)

Watch live: Senate HELP committee grills Novo Nordisk on weight loss drug pricing

(2:14:30)

Life-changing careers at Novo Nordisk

(1:40)

Novo Nordisk CEO on Catalent, Ozempic and Wegovy

(13:6)